PubMed=3934070
Lenoir G.M., Vuillaume M., Bonnardel C.
The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma.
IARC Sci. Publ. 60:309-318(1985)

PubMed=3027441; DOI=10.1093/jnci/78.2.235
Cohen J.H.M., Revillard J.-P., Magaud J.-P., Lenoir G.M., Vuillaume M., Manel A.-M., Vincent C., Bryon P.-A.
B-cell maturation stages of Burkitt's lymphoma cell lines according to Epstein-Barr virus status and type of chromosome translocation.
J. Natl. Cancer Inst. 78:235-242(1987)

PubMed=1356511; DOI=10.1182/blood.V80.7.1781.1781
Gaidano G., Hauptschein R.S., Parsa N.Z., Offit K., Rao P.H., Lenoir G.M., Knowles D.M., Chaganti R.S.K., Dalla-Favera R.
Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma.
Blood 80:1781-1787(1992)

PubMed=19358282; DOI=10.1002/ijc.24351
Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M., Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.
Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC.
Int. J. Cancer 125:212-221(2009)